Female Sex Powder Anti Depression Drug Flibanserin Flibanserin Powder Cas 167933-07-5

Character:

Flibanserin is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with problems. Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain.

Flibanserin, sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive desire disorder (HSDD). The medication increases the number of satisfying events per month by about one half over placebo from a starting point of about two to three. The certainty of the estimate is low

Description:

Flibanserin is a drug developed to treat hypoactive desire disorder (HSDD) in women. Women with HSDD have a chronic lack of interest in sex that cannot be explained by another medical condition. HSDD is also accompanied by feelings of distress.

More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine and decreasing serotonin. In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying events, increase the intensity of desire and decrease the associated distress women feel from its loss.

Usage And Dosage:  

Flibanserin is used for hypoactive desire disorder among women. Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had "satisfying events". In those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of "satisfying events" from 2.7 to 3.7 times a month. The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.

Application:

HSDD is the most commonly reported form of female dysfunction. HSDD is defined as a persistent or recurrent deficiency or absence of fantasies and desire for activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a medical, substance-related , psychiatric (e.g., depression) or other condition. The cause of HSDD is believed to involve a multitude of social, psychological and biological factors and may be attributed to a complex interplay of these factors.

Flibanserin is a novel, nonhormonal drug that has been studied in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect desire. More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine (both responsible for excitement) and decreasing serotonin (responsible for inhibition). In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying events, increase the intensity of desire and decrease the associated distress women feel from its loss.

Female Sex Powder Flibanserin Flibanserin powder Cas 167933-07-5